OrthoPediatrics stock
KIDSNASDAQOrthoPediatrics Corp., HealthcareISIN US68752L1008
47Score 47 out of 100, Weak
Price and trend
82 / 100
Price history
+96% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 67% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 76).
The price is at its 52-week high. Largest decline in 9 years: 80% (November 2021 to April 2026).
Chart figures for advanced users
- SMA 50$24.68
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$20.13
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)76
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.64
- The lowest closing price of the last twelve months.
- Resistance$33.99
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- OrthoPediatrics Corp. belongs to the Medical (Devices) industry (United States) and, with a market value of $879.14M, is number 62 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $236.35M (up 15.4% year on year) and a loss of $39.65M.
- For fiscal 2026, analysts expect on average revenue of $271.6M (up 14.9%) and adjusted earnings per share of −$1.20.
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 426 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 27.2% a year since 2020, Medical (Devices) median 13.8%.Growth 70
Weaknesses
- DilutionShare count up 30% since 2020.Capital allocation 18
- Loss-makingLoss of $33.88M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 52% a year over the last 12 months.Stability 57
Its standout strengths are momentum and technical analysis, while fundamentals and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price up very strongly over the past year
- high price swings
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
OvervaluedNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 16.1% on the twelve months before. Revenue has grown strongly since 2014, at around 23% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 73%, operating −12%, net −17%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 27 Oct 2026EPS reported −$0.23 (expected −$0.21)below expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 3.7% since 15 Oct 2026.
- Earnings per share
- −$1.20+0.9%
- Revenue
- $271.6M+1.7%
- Earnings per share
- −$0.79+3.7%
- Revenue
- $304.47M+1.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +28.2%OrthoPediatrics raised its 2026 revenue guidance to $270 million to $273 million, representing 14% to 16% growth versus 11% to 13% before, while reaffirming adjusted EBITDA guidance of about $25 million.
“We are raising our full year 2026 revenue guidance to be in the range of $270 million to $273 million, representing growth of 14% to 16%. We are also reiterating our adjusted EBITDA guidance of approximately $25 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $15.58M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Pelizzon David R, Pritzker Jennifer N., Squadron Capital LLCSale
10 Sept 2026, Board
- Shares
- 302,369
- Price
- $21.01
- Value
- $6.35M
- Pelizzon David R, Pritzker Jennifer N., Squadron Capital LLCSale
2 Sept 2026, Board
- Shares
- 22,500
- Price
- $23.35
- Value
- $525,375
- Pelizzon David R, Pritzker Jennifer N., Squadron Capital LLCSale
1 Sept 2026, Board
- Shares
- 10,131
- Price
- $23.10
- Value
- $234,026
Show 4 more
- Pelizzon David R, Pritzker Jennifer N., Squadron Capital LLCSale
28 Aug 2026, Board
- Shares
- 326,700
- Price
- $23.04
- Value
- $7.53M
- Pelizzon David R, Squadron Capital LLC, Pritzker Jennifer N.Sale
26 Aug 2026, Board
- Shares
- 18,000
- Price
- $24.28
- Value
- $437,040
- Pelizzon David R, Squadron Capital LLC, Pritzker Jennifer N.Sale
25 Aug 2026, Board
- Shares
- 16,300
- Price
- $24.74
- Value
- $403,262
- Pelizzon David R, Squadron Capital LLC, Pritzker Jennifer N.Sale
24 Aug 2026, Board
- Shares
- 4,000
- Price
- $25.75
- Value
- $103,000
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at OrthoPediatrics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- CeriBellCBLL $1.08B49
- AdaptHealthAHCO $1.06B33
- ArtivionAORT $980M32
- Kuros BiosciencesKURN.SW $962.93M47
- MedCapMCAP.ST $828.57M76
- Beta BionicsBBNX $801.27M47
- InModeINMD $790.08M72
- Varex ImagingVREX $780.9M53
ETFs that hold OrthoPediatrics
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.